loading
전일 마감가:
$112.77
열려 있는:
$112.41
하루 거래량:
1.82M
Relative Volume:
0.28
시가총액:
$143.03B
수익:
$28.80B
순이익/손실:
$6.31B
주가수익비율:
22.96
EPS:
5.02
순현금흐름:
$9.37B
1주 성능:
+1.87%
1개월 성능:
+2.33%
6개월 성능:
-0.31%
1년 성능:
+46.10%
1일 변동 폭
Value
$112.25
$115.27
1주일 범위
Value
$111.28
$115.25
52주 변동 폭
Value
$78.26
$121.83

길리어드 사이언스 Stock (GILD) Company Profile

Name
명칭
Gilead Sciences Inc
Name
전화
(650) 574-3000
Name
주소
333 LAKESIDE DR, FOSTER CITY, CA
Name
직원
17,600
Name
트위터
@GileadSciences
Name
다음 수익 날짜
2025-02-11
Name
최신 SEC 제출 서류
Name
GILD's Discussions on Twitter

GILD을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
115.27 139.93B 28.80B 6.31B 9.37B 5.02
Drug Manufacturers - General icon
LLY
Lilly Eli Co
730.58 665.99B 53.26B 13.80B -50.20M 15.30
Drug Manufacturers - General icon
JNJ
Johnson Johnson
179.03 430.51B 90.62B 22.66B 18.18B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
212.39 376.28B 58.33B 3.73B 18.24B 2.10
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
130.35 248.60B 53.40B 13.68B 16.89B 6.9231
Drug Manufacturers - General icon
MRK
Merck Co Inc
84.47 209.94B 63.43B 16.42B 14.72B 6.49

길리어드 사이언스 Stock (GILD) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-08-19 업그레이드 Daiwa Securities Neutral → Outperform
2025-08-08 업그레이드 Truist Hold → Buy
2025-07-25 업그레이드 Needham Hold → Buy
2025-04-22 재개 Cantor Fitzgerald Overweight
2025-03-04 재확인 Oppenheimer Outperform
2025-02-18 업그레이드 Deutsche Bank Hold → Buy
2025-02-13 업그레이드 DZ Bank Hold → Buy
2025-01-10 업그레이드 Morgan Stanley Equal-Weight → Overweight
2024-12-10 재개 BofA Securities Buy
2024-11-15 개시 Wolfe Research Outperform
2024-11-14 개시 Citigroup Buy
2024-11-08 다운그레이드 Maxim Group Buy → Hold
2024-10-21 업그레이드 Leerink Partners Market Perform → Outperform
2024-10-17 개시 Bernstein Outperform
2024-10-07 업그레이드 Wells Fargo Equal Weight → Overweight
2024-07-08 업그레이드 Raymond James Mkt Perform → Outperform
2024-05-01 재확인 Maxim Group Buy
2024-04-24 업그레이드 HSBC Securities Reduce → Hold
2024-02-22 다운그레이드 Truist Buy → Hold
2023-11-09 개시 Deutsche Bank Hold
2023-09-08 업그레이드 BofA Securities Neutral → Buy
2023-09-06 개시 HSBC Securities Reduce
2023-07-24 재확인 Barclays Equal Weight
2023-05-16 업그레이드 BMO Capital Markets Market Perform → Outperform
2023-04-28 재개 Piper Sandler Overweight
2023-01-03 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2022-12-13 재개 BofA Securities Neutral
2022-12-09 다운그레이드 DZ Bank Buy → Hold
2022-10-31 업그레이드 Barclays Underweight → Equal Weight
2022-10-28 재확인 BMO Capital Markets Market Perform
2022-10-28 재확인 Cowen Outperform
2022-10-28 재확인 JP Morgan Overweight
2022-10-28 재확인 Jefferies Buy
2022-10-28 업그레이드 Piper Sandler Neutral → Overweight
2022-10-28 재확인 RBC Capital Mkts Outperform
2022-10-28 업그레이드 Truist Hold → Buy
2022-10-28 재확인 Wells Fargo Equal Weight
2022-10-04 업그레이드 JP Morgan Neutral → Overweight
2022-07-13 개시 Cantor Fitzgerald Neutral
2022-05-23 개시 SVB Leerink Mkt Perform
2022-02-28 다운그레이드 BMO Capital Markets Outperform → Market Perform
2022-02-02 재확인 BMO Capital Markets Outperform
2022-02-02 재확인 BofA Securities Neutral
2022-02-02 재확인 RBC Capital Mkts Outperform
2022-02-02 재확인 Truist Hold
2022-02-02 재확인 Wells Fargo Equal Weight
2022-01-28 업그레이드 Argus Hold → Buy
2022-01-06 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-12-09 재개 Wells Fargo Equal Weight
2021-12-06 개시 Goldman Neutral
2021-11-19 업그레이드 BMO Capital Markets Market Perform → Outperform
2021-11-19 재개 Piper Sandler Neutral
2021-10-20 재개 Cowen Outperform
2021-07-30 재확인 BMO Capital Markets Market Perform
2021-07-30 재확인 RBC Capital Mkts Outperform
2021-04-01 업그레이드 Bernstein Mkt Perform → Outperform
2021-03-30 업그레이드 Redburn Neutral → Buy
2021-01-19 업그레이드 Morgan Stanley Equal-Weight → Overweight
2021-01-04 업그레이드 Guggenheim Neutral → Buy
2020-11-03 재개 Morgan Stanley Equal-Weight
2020-10-28 개시 UBS Neutral
2020-09-30 재개 Jefferies Buy
2020-09-15 업그레이드 Maxim Group Hold → Buy
2020-07-31 재확인 Credit Suisse Neutral
2020-07-31 재확인 Morgan Stanley Equal-Weight
2020-07-31 재확인 Piper Sandler Overweight
2020-07-31 재확인 RBC Capital Mkts Outperform
2020-07-31 재확인 SunTrust Hold
2020-07-31 재확인 Wells Fargo Equal Weight
2020-07-20 업그레이드 Credit Suisse Underperform → Neutral
2020-06-03 업그레이드 SVB Leerink Mkt Perform → Outperform
2020-05-26 업그레이드 SunTrust Sell → Hold
2020-05-01 다운그레이드 JP Morgan Overweight → Neutral
2020-05-01 다운그레이드 Raymond James Outperform → Mkt Perform
2020-05-01 다운그레이드 SunTrust Hold → Sell
2020-04-27 다운그레이드 UBS Buy → Neutral
2020-04-20 다운그레이드 BMO Capital Markets Outperform → Market Perform
2020-04-20 다운그레이드 Wells Fargo Overweight → Equal Weight
2020-04-17 다운그레이드 CFRA Hold → Sell
모두보기

길리어드 사이언스 주식(GILD)의 최신 뉴스

pulisher
11:26 AM

FDA to publish CRLs in real time; PEPFAR to distribute Gilead’s Yeztugo - BioPharma Dive

11:26 AM
pulisher
10:56 AM

Gilead Announces Partnership With PEPFAR - Contract Pharma

10:56 AM
pulisher
08:33 AM

Gilead Partners With US State Department to Distribute Yeztugo to Low-Income Countries - BioSpace

08:33 AM
pulisher
07:04 AM

Rx Rundown: Novartis, Gilead Sciences, Remedy Meds and more - Medical Marketing and Media

07:04 AM
pulisher
07:01 AM

What to expect from Gilead Sciences Inc. in the next 30 daysMarket Trend Review & Low Risk Profit Maximizing Plans - Newser

07:01 AM
pulisher
05:11 AM

Gilead breaks ground on AI-enabled US manufacturing hub - European Pharmaceutical Review

05:11 AM
pulisher
05:09 AM

Gilead Sciences’ Strategic Expansion in HIV Prevention and Global Access: Assessing Long-Term Investment Potential - AInvest

05:09 AM
pulisher
05:00 AM

Gilead Sciences advances HIV prevention with new US partnership - Yahoo Finance

05:00 AM
pulisher
02:50 AM

Momentum divergence signals in Gilead Sciences Inc. chartWeekly Trade Analysis & Risk Controlled Daily Trade Plans - Newser

02:50 AM
pulisher
02:22 AM

Price action breakdown for Gilead Sciences Inc.2025 Volatility Report & Long-Term Growth Stock Strategies - Newser

02:22 AM
pulisher
01:48 AM

Stock Analysis | Gilead Sciences OutlookA Strong Technical Picture with Mixed Analyst Signals - AInvest

01:48 AM
pulisher
Sep 04, 2025

What earnings revisions data tells us about Gilead Sciences Inc.Trade Entry Report & Step-by-Step Swing Trade Plans - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead joins U.S. efforts in expanding access to new HIV drug in low-income nations - Seeking Alpha

Sep 04, 2025
pulisher
Sep 04, 2025

US plans to bring Gilead HIV drug to market in high-burden HIV countries - Reuters

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead partners with PEPFAR to expand HIV prevention access - Investing.com

Sep 04, 2025
pulisher
Sep 04, 2025

U.S. to bring Gilead’s HIV drug lenacapavir to high-burden countries - Investing.com

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries - Business Wire

Sep 04, 2025
pulisher
Sep 04, 2025

US Plans to Bring Gilead HIV Drug to Market in High-Burden HIV Countries - U.S. News & World Report

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead Sciences to Offer Lenacapavir at Cost for Global HIV Prevention - Devdiscourse

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead at Wells Fargo Conference: Strategic Growth and Challenges - Investing.com

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead Sciences breaks ground on new manufacturing hub - The Pharma Letter

Sep 04, 2025
pulisher
Sep 04, 2025

Australia Acute Respiratory Distress Syndrome Market Growth and Company Report 2025-2033 Featuring Silence Therapeutics, Gilead Sciences, Terumo, Getinge, Livanova, Medtronic, Fresenius, Nipro, Pfizer - GlobeNewswire

Sep 04, 2025
pulisher
Sep 04, 2025

'I can't wait to see where we go': Gilead launches $32 billion U.S. investment with new Foster City building - The Business Journals

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead Breaks Ground on Pharmaceutical Development & Manufacturing Technical Development Center - Contract Pharma

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead Sciences describes new Mpro inhibitors for SARS-CoV-2 - BioWorld MedTech

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead begins construction of new manufacturing centre in US - World Pharmaceutical Frontiers

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead Sciences Launches Choose U Campaign Spotlighting the Inspiring Experiences of People Living with HIV - Business Wire

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead, Amgen kick off facility investments in US - pharmaphorum

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead Sciences Launches Choose U™ Campaign Spotlighting the Inspiring Experiences of People Living with HIV - Bakersfield.com

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead unveils new California manufacturing site, part of $32B US investment - FirstWord Pharma

Sep 04, 2025
pulisher
Sep 04, 2025

Gilead Sciences Breaks Ground on New Manufacturing Hub, a Cornerstone of Its U.S. Growth and Innovation Strategy - BioSpace

Sep 04, 2025
pulisher
Sep 04, 2025

Is Gilead Sciences Stock Underperforming the Nasdaq? - MSN

Sep 04, 2025
pulisher
Sep 04, 2025

Is Gilead Sciences Stock Underperforming The Nasdaq? - Barchart.com

Sep 04, 2025
pulisher
Sep 03, 2025

GILD Stock Quote Price and Forecast - CNN

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead breaks ground on AI-enabled biopharma hub at Foster City headquarters - KRON4

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead starts building manufacturing hub under $32 billion planned US investments - Reuters

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead Sciences’ Strategic Position in the Evolving Biopharma Landscape - AInvest

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead breaks ground on Foster City manufacturing hub as $32B US investment plan plays out - Fierce Pharma

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead at Cantor Global Healthcare Conference: Strategic Focus on Innovation - Investing.com

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead Sciences' $32 Billion U.S. Expansion and Its Implications for Biopharma Innovation and Stock Value - AInvest

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead Sciences $32B Investment in US Pharma ManufacturingNews and Statistics - IndexBox

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead Sciences’ $32 Billion U.S. Expansion and Its Implications for Biopharma Leadership - AInvest

Sep 03, 2025
pulisher
Sep 03, 2025

4 Questions on Gilead’s New Technical Development Center with Stacey Ma & Jamie Moore - Gilead Sciences

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead Sciences Breaks Ground on New Manufacturing Center at California HQ - MarketScreener

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead's $32 Billion US Manufacturing Expansion: A Strategic Catalyst for Long-Term Shareholder Value - AInvest

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead breaks ground on manufacturing development site at California HQ - Seeking Alpha

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead breaks ground on new Bay Area facility as part of $32 billion investment By Investing.com - Investing.com

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead Sciences' $32 Billion U.S. Investment: A Strategic Catalyst for Biopharma Innovation and Shareholder Value - AInvest

Sep 03, 2025
pulisher
Sep 03, 2025

Gilead Sciences breaks ground on new manufacturing facility in Foster City - StreetInsider

Sep 03, 2025
pulisher
Sep 03, 2025

Intraday pattern recognizer results for Gilead Sciences Inc.Market Risk Analysis & Growth Focused Entry Reports - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Will Gilead Sciences Inc. stock go up soon2025 Dividend Review & Community Consensus Trade Alerts - Newser

Sep 03, 2025

길리어드 사이언스 (GILD) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_general PFE
$24.68
price up icon 0.55%
$282.71
price up icon 1.02%
drug_manufacturers_general SNY
$46.49
price up icon 2.37%
drug_manufacturers_general NVO
$55.36
price down icon 1.34%
drug_manufacturers_general MRK
$84.54
price up icon 0.53%
자본화:     |  볼륨(24시간):